Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

Fig. 2

Intensity of the immunostaining for Iba-1 (bottom right panel) measured in a selected area of the substantia nigra pars compacta of adult male mice at 3 weeks of being subjected to an intrastriatal injection of LPS and daily treated with VCE-003.2 (10 mg/kg), alone or combined with T0070907 (5 mg/kg), or vehicle. Immunoreactivity values are measures in the lesioned side over the non-lesioned side and correspond to means ± SEM of 4–6 subjects per group. Data were assessed by the one-way analysis of variance followed by the Student–Newman–Keuls test (*p < 0.05, **p < 0.01 versus vehicle-treated control mice; #p < 0.05 versus VCE-003.2-treated LPS-lesioned mice). Representative Iba-1 immunostaining images for each experimental group are shown in the top and left panels (scale bar = 100 μm), including a specific inlet showing the morphological characteristics of Iba-1-labeled cells (scale bar = 25 μm)

Back to article page